{"text": "reuters the u s food and drug administration will expedite its review of eisai co ltds and biogen incs experimental alzheimers drug lecanemab with a decision due by jan 6 2023 the companies said on tuesday biib"}
{"text": "biib the u s fda accepts and grants priority review for eisai s biologics license application of lecanemab for early alzheimer s disease under the accelerated approval pathway"}
{"text": "the u s fda accepts and grants priority review for eisai s biologics license application of lecanemab for early alzheimer s disease under the accelerated approval pathway biib"}
{"text": "biib the u s fda accepts and grants priority review for eisai s biologics license application of lecanemab for early alzheimer s disease under the accelerated approval pathway 45 seconds delayed"}
{"text": "biib the u s fda accepts and grants priority review for eisai s biologics license application of lecanemab for early alzheimer s disease under the accelerated approval pathway stock news alerts in bio"}
{"text": "this is how we make money with trade ideas biib biib"}
